Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Tissum rases €39m

November 21, 2019 By Sean Whooley

Programmable polymer developer Tissium announced that it raised nearly $43 million in a Series B funding round to support expansion. The company’s funding round reached approximately $42.8 million (€38.8 million) and included new investors BNP Paribas Developpement, the European Investment Fund, M&L Investments and ValQuest Partners, along with returning investors Bpifrance, CM-CIC Innovation, CapDecisif Management, […]

Filed Under: Business/Financial News, Featured, Funding Roundup, Personnel Tagged With: Brigham & Women's Hospital, Mass. Institute of Technology, Tissium

High-capacity nanoparticle holds potential for targeted cancer therapies

September 15, 2016 By Sarah Faulkner

High-capacity nanoparticle holds potential for targeted cancer therapies

Chemists from the Mass. Institute of Technology developed a nanoparticle that they can pack with 3 or more drugs to create custom combination therapies for cancer, according to a study published this week in the Journal of the American Chemical Society. The team also revealed that cisplatin, a powerful anti-cancer drug, doesn’t work using the […]

Filed Under: Drug-Device Combinations, Oncology, Research & Development Tagged With: Mass. Institute of Technology

MassDevice.com +3 | Baxter's CEO reaps $14M, Sapien trial cut short on adverse events, Devices plus drugs pose great potential

November 10, 2011 By drugdelivery

Plus 3

Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This latest feature of MassDevice.com’s coverage highlights our three biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.

If you read nothing else today, make sure you’re still in the know with MassDevice +3.

Filed Under: Drug-Device Combinations Tagged With: Baxter International, Edwards Lifesciences, Mass. Institute of Technology

Devices plus drugs may mean an earlier payoff

November 9, 2011 By drugdelivery

Michael Cima

Michael Cima

Companies combining valuable devices with known drugs may be able to land a high-value exit before ever hitting the market, MIT researcher Michael Cima told a group of medical device industry leaders today.

Speaking at the Cooley Medical Device Growth conference in Boston, Cima urged med-tech companies and investors to consider drug-device combinations, acknowledging a higher up-front risk with the potential for an earlier and larger reward.

Filed Under: Drug-Device Combinations Tagged With: Cooley LLP, Mass. Institute of Technology

Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookDrug Delivery Business News
Follow us on Twitter@DrugDeliveryNow
Connect with us on LinkedInLinkedIn

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS